MedTrace Logo

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

NCT04175470 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-01-03

No results posted yet for this study

Summary

A recent study at the Department of Oncology, Vejle Hospital (NCT02399592), investigated bevacizumab and tocotrienol in ovarian cancer patients and concurrently monitored the level of methylated HOXA9 circulating tumor DNA (HOXA9 meth-ctDNA) in the blood.

The rate of disease control was 70% with better results than other studies using bevacizumab alone. The toxicity was very low and attributed to bevacizumab only.

When the study results were worked up they showed that patients with a significant increase of HOXA9 meth-ctDNA after the first cycle of treatment did not benefit from the treatment whereas those with stable or decreasing HOXA9 meth-ctDNA did.

Therefore, in the current study patients with a high increase of HOXA9 meth-ctDNA after the first treatment cycle will discontinue treatment, as it is then considered ineffective. The remaining patients may achieve prolonged survival as predicted by their level of HOXA9 meth-ctDNA.

Conditions

  • Ovarian Cancer Recurrent

Interventions

DRUG

Bevacizumab

10 mg/kg intravenously every three weeks

DIETARY_SUPPLEMENT

Tocotrienol

Capsules, 300 mg orally three times daily

Sponsors & Collaborators

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Torben F Hansen, MD, DMSc · Department of Oncology, Vejle Hospital - University Hospital of Southern Denmark

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-29
Primary Completion
2024-07-30
Completion
2024-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04175470 on ClinicalTrials.gov